A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Name: A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
Published: 2017
License: Public Domain

Novartis Pharmaceuticals · 2017

ClinicalTrials.gov · Datasets · License: Public Domain · 2017

Open Source ↗

elderly prevention

alzheimers disease, placebo controlled, apoe4 carriers, homozygotes, heterozygotes, brain amyloid, aβ lowering, bace-1 inhibitor, cnp520, elderly, preclinical alzheimers disease, prevention

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 861923
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.